Globally, the rise in research expenditures, deterioration in human health conditions and the need for novel and effective therapies have boosted the demand for drug discovery tools. In just the last few years, the drug discovery and development industry has undergone a major transition, with increased calls for efficient, user-friendly and affordable products. A new study by BCC Research examines all aspects of the drug discovery process, which consumes a major portion of drug development costs. Therefore, it is imperative for companies to use technologies that offer a high probability that their future drug product will be commercially successful.
On January 31, 2018, BCC Research analyst Smruti Munshi presented a Member-exclusive webinar on the future of mobile apps for DNA sequencing, and more specifically, smartphone apps used to interpret the data for both genealogical and medical applications. The technology is in a nascent stage, and the possibilities are seemingly endless. Senior Editor Chris Spivey captures the frontier-nature of DNA sequencing in his introduction, which is transcribed below.
The development of novel enzyme inhibitors has led to effective therapeutic options for diseases that were once considered difficult to treat. A newly updated study by BCC Research finds that approvals of new molecular entities will drive the global market for enzyme inhibitors to $179.9 billion by 2022. Enzyme inhibitors offer therapeutic options for myriad illnesses, including HCV, HIV, cancer, gastrointestinal disease, cardiovascular disease, inflammatory disorders, rheumatoid arthritis, neurological disorders (depression, Parkinson’s disease, Alzheimer’s disease) and diabetes.